Modality
Radioligand
MOA
BiTE
Target
HER2
Pathway
Notch
Schizophrenia
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Feb 2030
Phase 1Current
NCT03284498
2,510 pts·Schizophrenia
2017-03→2030-02·Completed
2,510 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-143.9y awayPh2 Data· Schizophrenia
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1/2
Complet…
Catalysts
Ph2 Data
2030-02-14 · 3.9y away
Schizophrenia
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03284498 | Phase 1/2 | Schizophrenia | Completed | 2510 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 |